Three Components, One Integrated Solution for Acute Respiratory Failure
The HEMOLUNG is the first and only FDA cleared extracorporeal CO2 removal (ECCO2R) device.
The HEMOLUNG rapidly corrects hypercapnia and respiratory acidosis which can enable avoidance of intubation and de-escalation of mechanical ventilation.
The HEMOLUNG is specifically designed to minimize the risks and complexities of extracorporeal lung support enabling the HEMOLUNG to be used in variety of hospital settings without specialized extracorporeal experience.
Indication for Use: The HEMOLUNG is indicated for respiratory support that provides extracorporeal carbon dioxide (CO2) removal from the patient’s blood for up to 5 days in adults with acute, reversible respiratory failure for whom ventilation of CO2 cannot be adequately or safely achieved using other available treatment options and continued clinical deterioration is expected.